[go: up one dir, main page]

AR124513A2 - Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento - Google Patents

Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento

Info

Publication number
AR124513A2
AR124513A2 ARP210103668A ARP210103668A AR124513A2 AR 124513 A2 AR124513 A2 AR 124513A2 AR P210103668 A ARP210103668 A AR P210103668A AR P210103668 A ARP210103668 A AR P210103668A AR 124513 A2 AR124513 A2 AR 124513A2
Authority
AR
Argentina
Prior art keywords
immunoglobulin
mip
antibody
heavy chain
binding
Prior art date
Application number
ARP210103668A
Other languages
English (en)
Inventor
Nicolas Baurin
Christian Beil
Carsten Corvey
Christian Lange
Danxi Li
Vincent Mikol
Anke Steinmetz
Ercole Rao
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46927552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR124513(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR124513A2 publication Critical patent/AR124513A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona proteínas de unión de tipo anticuerpo que comprenden cuatro cadenas polipeptídicas que forman cuatro sitios de unión al antígeno, donde cada par de polipéptidos que forman una proteína de unión de tipo anticuerpo posee dominios variables duales que tienen una orientación entrecruzada. La invención también proporciona métodos para elaborar tales proteínas de unión de tipo antígeno. Reivindicación 1: Una proteína de unión de tipo anticuerpo caracterizada porque comprende cuatro cadenas polipeptídicas que forman cuatro sitios de unión al antígeno, donde dos cadenas polipeptídicas tienen una estructura representada por la fórmula: VL₁-L₁-VL₂-L₂-CL [I] y dos cadenas polipeptídicas comprenden una estructura representada por la fórmula: VH₂-L₃-VH₁-L₄-CH₁-Fc [II] donde: VL₁ es un primer dominio variable de la cadena ligera de la inmunoglobulina; VL₂ es un segundo dominio variable de la cadena ligera de la inmunoglobulina; VH₁ es un primer dominio variable de la cadena pesada de la inmunoglobulina; VH₂ es un segundo dominio variable de la cadena pesada de la inmunoglobulina; CL es un dominio constante de la cadena ligera de la inmunoglobulina; CH₁ es un dominio constante de la cadena pesada CH₁ de la inmunoglobulina; Fc es una región bisagra de inmunoglobulina y los dominios constantes de cadena pesada de inmunoglobulina CH₂ y CH₃ derivan de un dominio Fc; y L₁, L₂, L₃ y L₄ son conectores aminoacídicos, donde L₁, L₂, L₃ y L₄ tienen una longitud de aminoácidos de acuerdo con una de las siguientes combinaciones: L₁ = 0, L₂ = 2, L₃ = 2, L₄ = 4; L₁ = 0, L₂ = 2, L₃ = 4, L₄ = 4; L₁ = 1, L₂ = 1, L₃ = 2, L₄ = 4; L₁ = 1, L₂ = 2, L₃ = 0, L₄ = 0; L₁ = 1, L₂ = 2, L₃ = 0, L₄ = 2; L₁ = 1, L₂ = 2, L₃ = 0, L₄ = 4; L₁ = 1, L₂ = 2, L₃ = 1, L₄ = 4; L₁ = 1, L₂ = 2, L₃ = 12, L₄ = 12; L₁ = 1, L₂ = 2, L₃ = 15, L₄ = 15; L₁ = 1, L₂ = 2, L₃ = 2, L₄ = 2; L₁ = 1, L₂ = 2, L₃ = 2, L₄ = 4; L₁ = 1, L₂ = 2, L₃ = 2, L₄ = 7; L₁ = 1, L₂ = 2, L₃ = 4, L₄ = 4; L₁ = 1, L₂ = 2, L₃ = 4, L₄ = 7; L₁ = 1, L₂ = 2, L₃ = 6, L₄ = 4; L₁ = 1, L₂ = 2, L₃ = 6, L₄ = 7; L₁ = 1, L₂ = 2, L₃ = 9, L₄ = 12; L₁ = 1, L₂ = 3, L₃ = 2, L₄ = 4; L₁ = 1, L₂ = 4, L₃ = 2, L₄ = 4; L₁ = 2, L₂ = 2, L₃ = 2, L₄ = 4; L₁ = 5, L₂ = 5, L₃ = 1, L₄ = 2; L₁ = 7, L₂ = 3, L₃ = 1, L₄ = 2; L₁ = 7, L₂ = 5, L₃ = 1, L₄ = 2; L₁ = 10, L₂ = 3, L₃ = 1, L₄ = 2; L₁ = 10, L₂ = 5, L₃ = 1, L₄ = 2; L₁ = 7, L₂ = 5, L₃ = 2, L₄ = 0; L₁ = 5, L₂ = 5, L₃ = 2, L₄ = 2; L₁ = 7, L₂ = 5, L₃ = 2, L₄ = 2; L₁ = 10, L₂ = 3, L₃ = 2, L₄ = 2; L₁ = 10, L₂ = 5, L₃ = 2, L₄ = 2; L₁ = 10, L₂ = 6, L₃ = 6, L₄ = 0; L₁ = 12, L₂ = 6, L₃ = 6, L₄ = 0; L₁ = 10, L₂ = 8, L₃ = 8, L₄ = 0; L₁ = 12, L₂ = 6, L₃ = 8, L₄ = 0; L₁ = 12, L₂ = 8, L₃ = 8, L₄ = 0, o L₁ = 12, L₂ = 6, L₃ = 8, L₄ = 2; y donde los polipéptidos de fórmula [I] y los polipéptidos de fórmula [II] forman un par de cadena ligera-cadena pesada entrecruzadas. Reivindicación 4: La proteína de unión de tipo anticuerpo de la reivindicación 3, caracterizada porque las una o más dianas antigénicas se seleccionan del grupo que consiste en B7.1, B7.2, BAFF, BlyS, C3, C5, CCL11 (eotaxina), CCL15 (MIP-1d), CCL17 (TARC), CCL19 (MIP3b), CCL2 (MCP-1), CCL20 (MIP-3a), CCL21 (MIP-2), SLC, CCL24 (MPIF-2 / eotaxina 2), CCL25 (TECK), CCL26 (eotaxina 3), CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CD3, CD19, CD20, CD24, CD40, CD40L, CD80, CD86, CDH1 (cadherina E), Quitinasa, CSF1 (M-CSF), CSF2 (GM-CSF), CSF3 (GCSF), CTLA4, CX3CL1 (SCYD1), CXCL12 (SDF1), CXCL13, EGFR, FCER1A, FCER2, HER2, IGF1R, IL-1, IL-12, IL13, IL15, IL17, IL18, IL1A, IL1B, IL1F10, IL2, IL4, IL6, IL7, IL8, IL9, IL12/23, IL22, IL23, IL25, IL27, IL35, ITGB4 (integrina b 4), LEP (leptina), MHC clase II, TLR2, TLR4, TLR5, TNF, TNFa, TNFSF4 (ligando OX40), TNFSF5 (ligando CD40), receptores de tipo Toll, TREM1, TSLP, TWEAK, XCR1 (GPR5 / CCXCR1), DNGR-1 (CLEC91) y HMGB1.
ARP210103668A 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento AR124513A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161468276P 2011-03-28 2011-03-28
FR1160311 2011-11-14

Publications (1)

Publication Number Publication Date
AR124513A2 true AR124513A2 (es) 2023-04-05

Family

ID=46927552

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP120101045A AR085726A1 (es) 2011-03-28 2012-03-28 Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento
ARP210103668A AR124513A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
ARP210103667A AR124512A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
ARP210103666A AR124511A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120101045A AR085726A1 (es) 2011-03-28 2012-03-28 Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP210103667A AR124512A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
ARP210103666A AR124511A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento

Country Status (32)

Country Link
US (7) US20120251541A1 (es)
EP (4) EP3112380A1 (es)
JP (6) JP6023172B2 (es)
KR (3) KR101974901B1 (es)
CN (3) CN110256569B (es)
AR (4) AR085726A1 (es)
AU (1) AU2012236603B2 (es)
BR (3) BR122022004041B1 (es)
CA (1) CA2831603C (es)
CL (1) CL2018001827A1 (es)
CO (1) CO6781527A2 (es)
CY (1) CY1118807T1 (es)
DK (2) DK3199547T3 (es)
ES (1) ES2588306T3 (es)
HR (1) HRP20161030T1 (es)
HU (1) HUE028230T2 (es)
IL (4) IL299392B2 (es)
LT (1) LT2691416T (es)
MA (1) MA35051B1 (es)
MX (1) MX338907B (es)
MY (1) MY164906A (es)
PH (1) PH12013502024A1 (es)
PL (2) PL2691416T3 (es)
PT (1) PT2691416T (es)
RS (2) RS55014B1 (es)
RU (1) RU2695880C2 (es)
SG (1) SG193916A1 (es)
SI (2) SI2691416T1 (es)
TW (6) TWI622597B (es)
UY (1) UY33983A (es)
WO (1) WO2012135345A1 (es)
ZA (1) ZA201307017B (es)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK3029066T3 (da) 2010-07-29 2019-05-20 Xencor Inc Antistoffer med modificerede isoelektriske punkter
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
PL2814843T3 (pl) 2012-02-13 2020-11-16 Agency For Science, Technology And Research Ludzkie przeciwciała monoklonalne neutralizujące IL-β
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
RS57748B1 (sr) 2012-09-12 2018-12-31 Genzyme Corp Polipeptidi sa izmenjenom glikozilacijom i smanjenom efektorskom funkcijom koji sadrže fc
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
EP2938636A2 (en) * 2012-12-28 2015-11-04 AbbVie Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP2016515093A (ja) * 2013-02-05 2016-05-26 サノフイ 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤
WO2014164503A1 (en) 2013-03-11 2014-10-09 Genzyme Corporation Hyperglycosylated binding polypeptides
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
US9481729B2 (en) * 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6752148B2 (ja) * 2014-02-07 2020-09-09 マクマスター ユニバーシティー 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用
CN116333148A (zh) 2014-03-19 2023-06-27 建新公司 靶向模块的位点特异性糖工程化
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
CN104974258B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗hgf/dll4双特异性抗体、其制备方法和应用
US10647777B2 (en) 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
TWI745962B (zh) * 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
HUE043951T2 (hu) * 2014-07-18 2019-09-30 Sanofi Sa Eljárás rákgyanús beteg aflibercepttel történõ kezelése kimenetének elõrejelzésére
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
AU2015311913B2 (en) 2014-09-03 2019-09-12 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof
AU2015330869B2 (en) 2014-10-09 2021-07-08 Genzyme Corporation Glycoengineered antibody drug conjugates
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353409B2 (en) 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
CA2966776C (en) * 2014-12-19 2021-05-04 Alkermes, Inc. Single chain fc fusion proteins
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
EP3237005B1 (en) 2014-12-22 2024-09-18 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
EP3812398A3 (en) * 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
SG10201913297TA (en) 2015-03-13 2020-02-27 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016154290A1 (en) 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
WO2016196429A1 (en) 2015-06-03 2016-12-08 The Medical College Of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
EA201890041A1 (ru) * 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
MY191081A (en) 2015-07-23 2022-05-30 Boehringer Ingelheim Int Compound targetting il-23a and b-cell activating factor (baff) and uses thereof
EP3328885A1 (en) 2015-09-11 2018-06-06 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
WO2017059900A1 (en) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
JP2018530574A (ja) 2015-10-07 2018-10-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の加齢黄斑変性を治療する方法
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
WO2017074878A1 (en) * 2015-10-25 2017-05-04 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
CN109293777A (zh) * 2015-11-13 2019-02-01 叶才果 双功能抗体及其用途
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
RS64771B1 (sr) 2016-04-13 2023-11-30 Sanofi Sa Trispecifični i/ili trovalentni vezujući proteini
CN109476732B (zh) * 2016-04-13 2024-03-22 赛诺菲 三特异性和/或三价结合蛋白
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
CN110352070B (zh) 2016-06-14 2024-09-17 Xencor股份有限公司 双特异性检查点抑制剂抗体
US10335459B2 (en) 2016-06-22 2019-07-02 Alkermes, Inc. Compositions for modulating IL-10 immunostimulatory and anti-inflammatory properties
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2018037092A1 (en) 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CR20230179A (es) 2016-10-14 2023-06-12 Xencor Inc PROTEÍNAS DE FUSIÓN FC HETERODIMÉRICAS IL 15/IL15Ra (Divisional 2019-0229)
ES2848206T3 (es) 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
EP3529619B1 (en) 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
KR20240049621A (ko) * 2017-02-17 2024-04-16 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US10626169B2 (en) * 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
DK3583126T3 (da) 2017-02-17 2025-11-17 Sanofi Sa Multispecifikke bindingsmolekyler med specificitet for dystroglycan og laminin-2
SG11201909265QA (en) 2017-04-19 2019-11-28 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
CA3059769A1 (en) * 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
JP2020519285A (ja) * 2017-05-10 2020-07-02 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー 最適化された核酸抗体構築物
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
EP3694882B1 (en) * 2017-10-10 2024-06-19 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3706793A1 (en) 2017-11-08 2020-09-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
CN111655718B (zh) 2017-12-19 2025-07-22 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白
AR114080A1 (es) * 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
EP3737949A1 (en) 2018-01-12 2020-11-18 Genzyme Corporation Methods for the quantitation of polypeptides
CN111788221B (zh) 2018-01-26 2026-02-13 建新公司 具有与FcRn增强的结合及延长的半衰期的Fc变体
CA3093481A1 (en) * 2018-03-22 2019-09-26 Universitat Stuttgart Multivalent binding molecules
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CN113166254A (zh) 2018-10-09 2021-07-23 赛诺菲 三特异性抗cd38、抗cd28和抗cd3结合蛋白和用于治疗病毒感染的使用方法
US20220002393A1 (en) 2018-11-20 2022-01-06 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
SG11202106393SA (en) 2018-12-24 2021-07-29 Sanofi Sa Pseudofab-based multispecific binding proteins
MX2021007672A (es) * 2018-12-24 2021-09-30 Sanofi Sa Proteinas de union multiespecificas con dominios fab mutantes.
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
MX2021012386A (es) * 2019-04-09 2022-01-18 Sanofi Sa Proteínas de union triespecíficas, métodos y usos de las mismas.
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP7661245B2 (ja) * 2019-06-07 2025-04-14 アムジエン・インコーポレーテツド 二重特異性結合構築物
CA3148764A1 (en) 2019-07-25 2021-01-28 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
EP4013783A1 (en) * 2019-08-15 2022-06-22 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
IL292480A (en) 2019-10-25 2022-06-01 Sanofi Sa Methods for the analysis of chain mispairs in multispecific binding proteins
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
KR20220148235A (ko) 2020-02-28 2022-11-04 젠자임 코포레이션 최적화된 약물 접합을 위한 변형된 결합 폴리펩티드
WO2021194839A1 (en) 2020-03-25 2021-09-30 Eli Lilly And Company Multispecific binding proteins and methods of developing the same
WO2021198204A1 (en) * 2020-03-30 2021-10-07 Sanofi Split ch2 domains
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
CN116648463A (zh) 2020-09-18 2023-08-25 伊克诺斯科学公司 Cd47-cd38双特异性抗体
TW202233237A (zh) 2020-11-18 2022-09-01 瑞士商諾華公司 用於在治療ｎｌｒｃ４－ｇｏｆ炎性體病變中使用的雙特異性抗體
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
WO2022219076A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4347640A1 (en) 2021-05-27 2024-04-10 Sanofi Fc variant with enhanced affinity to fc receptors and improved thermal stability
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
WO2023274342A1 (zh) * 2021-06-30 2023-01-05 江苏恒瑞医药股份有限公司 特异性结合baff和il-12/23的抗原结合分子及用途
AU2022357501A1 (en) * 2021-09-29 2024-04-18 Modex Therapeutics, Inc. Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv
US20230227553A1 (en) * 2021-09-29 2023-07-20 Modex Therapeutics Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
CA3236564A1 (en) 2021-11-02 2023-05-11 Visterra, Inc. Fc variants with abolished binding to fcgammar and c1q
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
PE20242075A1 (es) * 2022-03-03 2024-10-18 Pfizer Anticuerpos multiespecificos y usos de estos
US20240228650A9 (en) 2022-05-06 2024-07-11 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies
JP2025515915A (ja) 2022-05-18 2025-05-20 サノフイ 抗体のｐｋ値を予測するための方法、システム及び装置
EP4532023A1 (en) 2022-05-27 2025-04-09 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
EP4536676A2 (en) 2022-06-08 2025-04-16 Sanofi Methods for purification of multi-specific antibodies
EP4608859A1 (en) 2022-10-25 2025-09-03 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
WO2024121311A1 (en) 2022-12-07 2024-06-13 Ichnos Sciences SA Cd47/cd38 bispecific antibodies and methods of use to treat leukemia
WO2024126833A1 (en) 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
CN120936385A (zh) 2023-03-13 2025-11-11 海德堡医药研究有限责任公司 用于在癌症治疗中使用的皮下施用的抗体-药物缀合物
WO2025027003A1 (en) 2023-07-31 2025-02-06 Sanofi Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
WO2025233420A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use of anti-cancer molecules
WO2026022712A1 (en) 2024-07-23 2026-01-29 Sanofi Cereblon ligase modulator and bcma nk cell engager combination therapy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5837242A (en) * 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU6873396A (en) * 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
AU2507397A (en) 1996-04-04 1997-10-29 Unilever Plc Multivalent and multispecific antigen-binding protein
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
PL357939A1 (en) * 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
WO2002056910A1 (en) * 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL2158221T3 (pl) * 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
US9624309B2 (en) * 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
AU2009335798B2 (en) * 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP2014510730A (ja) * 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
EP3812398A3 (en) * 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
CN109476732B (zh) * 2016-04-13 2024-03-22 赛诺菲 三特异性和/或三价结合蛋白
EP3694882B1 (en) * 2017-10-10 2024-06-19 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
CN113166254A (zh) * 2018-10-09 2021-07-23 赛诺菲 三特异性抗cd38、抗cd28和抗cd3结合蛋白和用于治疗病毒感染的使用方法
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
JP6877371B2 (ja) 2021-05-26
EP3805262A1 (en) 2021-04-14
JP6490038B2 (ja) 2019-03-27
JP7603739B2 (ja) 2024-12-20
CN103562221A (zh) 2014-02-05
US20120251541A1 (en) 2012-10-04
KR102607708B1 (ko) 2023-11-30
ES2588306T3 (es) 2016-11-02
PT2691416T (pt) 2016-08-26
AR085726A1 (es) 2013-10-23
US20140056895A1 (en) 2014-02-27
AR124511A2 (es) 2023-04-05
TW201940510A (zh) 2019-10-16
CN110256569A (zh) 2019-09-20
MX338907B (es) 2016-05-05
US9181349B2 (en) 2015-11-10
JP7273135B2 (ja) 2023-05-12
KR20140019420A (ko) 2014-02-14
AR124512A2 (es) 2023-04-05
CN103562221B (zh) 2019-06-14
IL261674B (en) 2020-06-30
DK2691416T3 (en) 2016-09-05
IL261673A (en) 2018-10-31
BR122020011291B1 (pt) 2022-06-14
UY33983A (es) 2012-10-31
TW202212358A (zh) 2022-04-01
TW202317615A (zh) 2023-05-01
MY164906A (en) 2018-02-15
BR112013024758B1 (pt) 2022-06-14
US20210189011A1 (en) 2021-06-24
TWI622597B (zh) 2018-05-01
US20180155450A1 (en) 2018-06-07
TW201808994A (zh) 2018-03-16
KR20210042183A (ko) 2021-04-16
IL299392B2 (en) 2025-10-01
US9221917B2 (en) 2015-12-29
TW201302786A (zh) 2013-01-16
TWI803876B (zh) 2023-06-01
JP7003101B2 (ja) 2022-02-04
JP2018087211A (ja) 2018-06-07
LT2691416T (lt) 2016-09-12
CN110256568A (zh) 2019-09-20
IL299392A (en) 2023-02-01
RS61399B1 (sr) 2021-02-26
US20160200811A1 (en) 2016-07-14
AU2012236603A1 (en) 2013-04-18
HUE028230T2 (en) 2016-12-28
IL228512B (en) 2018-10-31
TWI743461B (zh) 2021-10-21
PL3199547T3 (pl) 2021-06-14
IL261673B (en) 2020-06-30
EP2691416B1 (en) 2016-05-18
AU2012236603B2 (en) 2015-06-18
KR101974901B1 (ko) 2019-05-08
KR20230166147A (ko) 2023-12-06
CA2831603A1 (en) 2012-10-04
TWI671315B (zh) 2019-09-11
SI3199547T1 (sl) 2021-03-31
IL228512A0 (en) 2013-12-31
EP3112380A1 (en) 2017-01-04
PL2691416T3 (pl) 2016-11-30
IL261674A (en) 2018-10-31
DK3199547T3 (da) 2021-02-08
NZ616174A (en) 2015-10-30
RS55014B1 (sr) 2016-11-30
ZA201307017B (en) 2014-05-28
EP2691416A1 (en) 2014-02-05
CN110256569B (zh) 2025-01-07
TWI588156B (zh) 2017-06-21
EP3199547B1 (en) 2020-11-18
JP2014511684A (ja) 2014-05-19
SG193916A1 (en) 2013-11-29
HRP20161030T1 (hr) 2016-10-21
CL2018001827A1 (es) 2018-08-31
US20130345404A1 (en) 2013-12-26
TW201722988A (zh) 2017-07-01
JP6023172B2 (ja) 2016-11-09
JP2022046668A (ja) 2022-03-23
BR112013024758A2 (pt) 2018-07-10
JP2020058363A (ja) 2020-04-16
EP3199547A1 (en) 2017-08-02
RU2013147821A (ru) 2015-05-20
PH12013502024A1 (en) 2013-12-16
RU2695880C2 (ru) 2019-07-29
IL299392B1 (en) 2025-06-01
TWI838039B (zh) 2024-04-01
JP2023100752A (ja) 2023-07-19
CA2831603C (en) 2020-07-21
CY1118807T1 (el) 2018-01-10
MX2013011176A (es) 2013-11-01
WO2012135345A1 (en) 2012-10-04
JP2017038607A (ja) 2017-02-23
SI2691416T1 (sl) 2016-10-28
US20140011238A1 (en) 2014-01-09
MA35051B1 (fr) 2014-04-03
BR122022004041B1 (pt) 2022-12-06
CO6781527A2 (es) 2013-10-31

Similar Documents

Publication Publication Date Title
AR124513A2 (es) Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
JP2018087211A5 (es)
Yi et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Sohn et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4
RU2767329C2 (ru) Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
US20200157249A1 (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201490020A1 (ru) Растворимые белки для применения в качестве терапевтических средств
CL2021001143A1 (es) Anticuerpos biespecificos y su uso.
WO2018225063A1 (en) Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
AR109264A1 (es) Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
AR114544A1 (es) Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
MX341074B (es) Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
UA117575C2 (uk) Антитіло, яке специфічно зв'язується з il-17a та його застосування
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
MX2024003913A (es) Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos.
CR20240246A (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
MX2022000779A (es) Anticuerpo monoclonal anti-vegf humanizado.
FI3443006T3 (fi) Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
HRP20210240T1 (hr) Vezujući proteini slični protutijelu s dvostrukom varijabilnom regijom koji imaju unakrsno orjentiranu vezujuću regiju
CO2025009570A2 (es) Moléculas de unión al antígeno que se unen a partículas de aav y usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure